secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001193125-25-177471
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo
--------------------------------------------------------------------------------

- Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.
- Median PFS 19.4 months (Cylembio+pembrolizumab) vs 11.0 months (pembrolizumab alone).
- PD-L1 negative subgroup median PFS 16.6 vs 3.0 months (HR 0.54, nominal p=0.006).
- OS trend HR=0.79 (CI 0.57-1.10); company expects OS maturity in 6-9 months.
- Estimated cash $28.1M as of June 30, plus €12.5M drawn July 4; runway into Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525177471/0001193125-25-177471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312525177471/d454108d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-177471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer